Patents by Inventor Douglas Stewart Williamson

Douglas Stewart Williamson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
    Patent number: 9675594
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of Formula A: The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 13, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors
    Publication number: 20170020850
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of Formula A: The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Applicants: H. Lundebck A/S, Vernalis (R&D) Ltd.
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
    Patent number: 9499542
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of formula (A) (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease cancer.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: November 22, 2016
    Assignees: H. Lundbeck A/S, Vernalis (R&D) Ltd.
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Aminopyridine derived compounds as LRRK2 inhibitors
    Patent number: 9393248
    Abstract: The present invention is directed to aminopyridine derived compounds of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such as a Lewy body dementia, Parkinson's disease or cancer.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 19, 2016
    Assignees: H. Lundbeck A/S, Vernalis (R&D) Ltd.
    Inventors: Gitte Kobberøe Mikkelsen, Laurent David, Stephen Watson, Garrick Paul Smith, Douglas Stewart Williamson, I-Jen Chen
  • Aminopyridine Derived Compounds as LRRK2 Inhibitors
    Publication number: 20160184317
    Abstract: The present invention is directed to aminopyridine derived compounds of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.
    Type: Application
    Filed: March 16, 2016
    Publication date: June 30, 2016
    Applicants: H. Lundbeck A/S, Vernalis (R&D) Ltd.
    Inventors: Gitte Kobberøe Mikkelsen, Laurent David, Stephen Watson, Garrick Paul Smith, Douglas Stewart Williamson, I-Jen Chen
  • Aminopyridine derived compounds as LRRK2 inhibitors
    Patent number: 9321748
    Abstract: The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: April 26, 2016
    Assignees: H. Lundbeck A/S, Vernalis (R&D) Ltd.
    Inventors: Gitte Kobberøe Mikkelsen, Laurent David, Stephen Watson, Garrick Paul Smith, Douglas Stewart Williamson, I-Jen Chen
  • Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
    Publication number: 20160102089
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of formula (A) (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease cancer.
    Type: Application
    Filed: April 14, 2014
    Publication date: April 14, 2016
    Applicants: H. Lundbeck A/S, Vernalis (R&D) Ltd.
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Aminopyridine derived compounds as LRRK2 inhibitors
    Publication number: 20150336942
    Abstract: The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.
    Type: Application
    Filed: December 30, 2013
    Publication date: November 26, 2015
    Inventors: Gitte Kobberøe Mikkelsen, Laurent David, Stephen Watson, Garrick Paul Smith, Douglas Stewart Williamson, I-Jen Chen
  • Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
    Publication number: 20140315901
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Pyrimidine Compounds as Purine Receptor Antagonist
    Publication number: 20080182860
    Abstract: Compounds of formula (1); wherein R1 is optionally substituted C1-C3alkyl C2-C3alkenyl, or C2-C3alkynyl, or —NR6R1, —ORB, —SR9 or halogen; R3 is II; optionally substituted C,-Csalkyl, C2-C6alkenyl, C2C6alkynyl, or C3-C7 cycloalkyl, halogen; OH or OR10; R4 is H, optionally substituted C1C6alkyl, C3-C6alkenyl, C3-C6alkynyl, C3-C7 cycloalkyl, aryl or heteroaryl, R5 is H or Optionally substituted C1-C6alkyl, C3-C6alkenyl, C3-C6alkynyl, or C3-C7 cycloalkyl; or R4 and R5 together form a 5 or 6-membered heterocyclic ring; and R7, R8, R9 and R10 are optionally substituted C1-C3alkyl, C2-C3alkenyl, C2-C3alkynyl, or C3-C7 cycloalkyl; are purine receptor, particularly adenosine receptor antagonists, useful for treatment of, inter alia, movement disorders such as Parkinsons disease.
    Type: Application
    Filed: February 11, 2005
    Publication date: July 31, 2008
    Applicant: VERNALIS (R&D) LTD.
    Inventors: Roger John Gillespie, Douglas Stewart Williamson